Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBurford Capital Regulatory News (BUR)

Share Price Information for Burford Capital (BUR)

Share Price is delayed by 15 minutes
Get Live Data
327.00    -8.40 (-2.50%)
Bid:
326.40
Ask:
328.00
Spread: 1.60 (0.49%)
Market Cap: £716.36m
BUR Live PriceLast checked at - London Stock Exchange

Intraday Burford Capital Share Chart

Strategic Relationship with Manolete

29 Jul 2013 08:00

RNS Number : 3091K
Burford Capital
29 July 2013
 



29 July 2013

 

BURFORD ANNOUNCES STRATEGIC RELATIONSHIP WITH MANOLETE

 

Burford Capital Limited ("Burford"), the world's largest provider of investment capital and risk solutions for litigation, announces a strategic relationship with Manolete Partners PLC ("Manolete"), the UK's leading insolvency litigation financier backed by Jon Moulton.

 

Burford will make a small investment in Manolete to become a 16% shareholder, matching Moulton's ownership interest. Under the arrangement, Burford will provide co-funding of up to £10 million for Manolete's insolvency litigation investments. Manolete is also backed by Punter Southall's P-Solve business, one of the UK's leading investment advisors.

 

Please see below for the joint press release issued today, which can also be accessed via the Burford Capital website www.burfordcapital.com

 

 

 

MANOLETE PARTNERS AND BURFORD CAPITAL FORM STRATEGIC RELATIONSHIP

Jon Moulton and Punter Southall-backed insolvency financier seeing strong growth

Burford becomes shareholder in and capital provider to Manolete

Manolete Partners PLC ("Manolete"), the UK's leading insolvency litigation financier, and Burford Capital Limited ("Burford"), the world's largest provider of investment capital and risk solutions for litigation, today announced a strategic relationship that will enable Manolete to continue its strong growth as a leader in the UK insolvency litigation market and increase Burford's exposure to this specialty business.

 

Under the arrangement, Burford will become a 16% shareholder in Manolete and will provide co-funding for Manolete's insolvency litigation investments. Both Manolete and Burford are seeing strong growth in the insolvency market and Burford has initially earmarked up to £10 million for its co-funding of Manolete's investments.

 

Manolete was founded in 2009 and has enjoyed growth of more than 100% each year since its formation. Manolete is backed by Jon Moulton, one of the UK's leading private equity investors, and Punter Southall's P-Solve business, one of the UK's leading investment advisors.

 

Steven Cooklin, Manolete's founder and Managing Director, said: "When I founded Manolete in 2009, after a successful corporate finance career at HSBC, I was intrigued with the unique opportunity to apply capital to the UK insolvency litigation market. Manolete has succeeded beyond my expectations, and Burford's capital and strategic collaboration will enable us to take Manolete far beyond the next level."

 

Christopher Bogart, Burford's Chief Executive, said: "The UK insolvency litigation market is a unique environment. It is not yet subject to the Jackson reforms and it permits the direct purchase of claims. Manolete has done a superb job of developing this market and we look forward to working with Steven and his team to continue Manolete's high growth strategy."

 

Jon Moulton commented: "Manolete has been very successful since I invested. This transaction with Burford, the litigation finance market leader, reaffirms my enthusiasm for Manolete. I look forward to working closely with Steven and Chris and their teams."

 

About Manolete:

 

Manolete is the UK's leading insolvency litigation financier. Manolete buys claims direct from insolvent companies and funds individual insolvency practitioners to pursue claims in their own name. Manolete operates across the entire UK insolvency industry where clients range from the large advisory groups including PwC, Deloittes, BDO, Grant Thornton, Begbies Traynor and RSM Tenon through to smaller regional firms and boutique operators such as Wilson Field, Moorfields, Leonard Curtis and Carter Clark.

For more information about Manolete, visit www.manolete-partners.com

 

About Burford:

 

Burford Capital is the world's largest provider of investment capital and risk solutions for litigation with more than $300 million in capital and the largest and most experienced dedicated team in the industry. Burford is publicly traded on the London Stock Exchange's AIM market under the ticker symbol BUR. Burford provides a broad range of corporate finance and insurance solutions to lawyers and clients engaged in significant litigation and arbitration around the world.

For more information about Burford, visit www.burfordcapital.com

 

For further information:

 

Manolete

Steven Cooklin Tel: +(44) 1494 618520 steven@manolete-partners.com

Managing Director

Manolete Partners PLC

 

Burford press inquiries via FTI Consulting

Edward Berry Tel: +(44) 20 7269 7297 edward.berry@fticonsulting.com

Laura Ewart Tel: +(44) 20 7269 7243 laura.ewart@fticonsulting.com

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAUWSKROOABUAR
Date   Source Headline
29th May 20262:00 pmRNSSterling FX Rate for 2025 Final Dividend
21st May 202612:00 pmRNSNotice of Retail Shareholder Audio Webcast
14th May 202612:00 pmRNSResult of AGM
8th May 202612:00 pmRNS1Q26 Financial Results
5th May 202612:00 pmRNSNotice of 1Q26 Results & Results Call Details
7th Apr 20267:00 amRNSHolding(s) in Company
31st Mar 20267:00 amRNSDirector/PDMR Shareholding & Issue of Equity
30th Mar 20267:00 amRNSBurford Capital Further Statement on YPF
30th Mar 20267:00 amRNSBurford Capital Statement Re YPF Appeal Decision
27th Mar 20263:32 pmRNSBurford Capital Statement re YPF Matter
17th Mar 202612:00 pmRNSCompletion of Share Repurchase Program
9th Mar 20261:45 pmRNSSubstantial Share Purchases by Executive Officers
9th Mar 20261:45 pmRNSSubstantial Share Purchases by Executive Officers
26th Feb 20261:00 pmRNSAnnual Results for Year Ended December 31, 2025
10th Feb 20261:00 pmRNSNotice of 2025 Results & Results Call Details
27th Jan 20261:30 pmRNSPricing of Early Redemption of Bonds Due 2026
15th Jan 20263:41 pmRNSNotice of Early Redemption of Bonds Due 2026
15th Jan 20267:00 amRNSHolding(s) in Company
14th Jan 20267:00 amRNSPricing and Upsizing of Senior Notes Offering
12th Jan 20262:01 pmRNSPrivate Offering of Senior Notes
5th Jan 20261:00 pmRNSIssue of New Shares in Connection with LTIP
23rd Dec 20257:00 amRNSDirector/PDMR Shareholding
23rd Dec 20257:00 amRNSDirector/PDMR Shareholding
19th Dec 20257:00 amRNSDirector/PDMR Shareholding
19th Dec 20257:00 amRNSDirector/PDMR Shareholding
10th Dec 20257:00 amRNSDirector/PDMR Shareholding
4th Dec 20251:00 pmRNSDirector/PDMR Shareholding
7th Nov 20251:00 pmRNSSterling Conversion Rate for 2025 Interim Dividend
6th Nov 20257:00 amRNSHolding(s) in Company
5th Nov 20251:00 pmRNSAppointment of Joint Corporate Broker
5th Nov 20251:00 pmRNS3Q25 and YTD25 Financial Results
29th Oct 20257:00 amRNSHolding(s) in Company
24th Oct 20257:00 amRNSHolding(s) in Company
23rd Oct 20251:00 pmRNSNotice of 3Q25 Results & Results Call Details
22nd Oct 20251:00 pmRNSYPF Matter Update
10th Oct 20257:00 amRNSHolding(s) in Company
3rd Oct 20257:00 amRNSDirector/PDMR Shareholding & New Share Issuance
1st Oct 20252:00 pmRNSHolding(s) in Company
29th Sep 20251:00 pmRNSInterim Dividend Declaration
29th Sep 20257:00 amRNSHolding(s) in Company
23rd Sep 20259:00 amRNSHolding(s) in Company
26th Aug 20257:00 amRNSDirector/PDMR Shareholding
7th Aug 20251:00 pmRNS2Q25 and YTD25 Financial Results
24th Jul 202512:00 pmRNSNotice of 2Q25 Results & Results Call Details
14th Jul 202512:00 pmRNSClosing of Private Offering of Senior Notes
14th Jul 20257:00 amRNSDirector/PDMR Shareholding
8th Jul 20255:21 pmRNSPricing and Upsizing of Senior Notes Offering
7th Jul 202512:57 pmRNSPrivate Offering of Senior Notes
3rd Jul 202511:00 amRNSIssue of New Shares in Connection With LTIP
2nd Jul 20255:30 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.